Advantages and Limitations of Cell Culture Models in Pediatric Drug Development Peter C. Adamson,...
-
Upload
gervais-francis -
Category
Documents
-
view
216 -
download
0
Transcript of Advantages and Limitations of Cell Culture Models in Pediatric Drug Development Peter C. Adamson,...
![Page 1: Advantages and Limitations of Cell Culture Models in Pediatric Drug Development Peter C. Adamson, M.D. The Children’s Hospital of Philadelphia.](https://reader036.fdocuments.us/reader036/viewer/2022062519/5697bfca1a28abf838ca9606/html5/thumbnails/1.jpg)
Advantages and Limitations of Cell Culture Models in Pediatric Drug Development
Peter C. Adamson, M.D.The Children’s Hospital of Philadelphia
![Page 2: Advantages and Limitations of Cell Culture Models in Pediatric Drug Development Peter C. Adamson, M.D. The Children’s Hospital of Philadelphia.](https://reader036.fdocuments.us/reader036/viewer/2022062519/5697bfca1a28abf838ca9606/html5/thumbnails/2.jpg)
Clonogenic Assay
Primary Bioassay of Human Tumor Stem Cells* Tumor stem cells are cell
renewal source and serve as seed of metastatic spread
Cytotoxicity in clonogenic assay proportional to cytotoxicity in vivo
*Hamburger AW, Salmon SE. Science, 197 (4302) 461-463; 1977.
![Page 3: Advantages and Limitations of Cell Culture Models in Pediatric Drug Development Peter C. Adamson, M.D. The Children’s Hospital of Philadelphia.](https://reader036.fdocuments.us/reader036/viewer/2022062519/5697bfca1a28abf838ca9606/html5/thumbnails/3.jpg)
Tritiated Thymidine Incorporation
3H-TdR measures cells in S-phase Quantifies cell number as cpm
![Page 4: Advantages and Limitations of Cell Culture Models in Pediatric Drug Development Peter C. Adamson, M.D. The Children’s Hospital of Philadelphia.](https://reader036.fdocuments.us/reader036/viewer/2022062519/5697bfca1a28abf838ca9606/html5/thumbnails/4.jpg)
Historical in vitro Assays
Clonogenic Assay Labor intensive Not readily amenable
to high throughput
3H-TdR Limitations of using
radioactivity Non-clonogenic method
![Page 5: Advantages and Limitations of Cell Culture Models in Pediatric Drug Development Peter C. Adamson, M.D. The Children’s Hospital of Philadelphia.](https://reader036.fdocuments.us/reader036/viewer/2022062519/5697bfca1a28abf838ca9606/html5/thumbnails/5.jpg)
Non-clonogenic Assays
MTT Assay Rapid colorimetric assay for cellular
growth and survival: application to proliferation and cytotoxcity assays*
*Mossman T. J Immunol Meth 1983;65:55-63.
N
N N
N
S
NCH3
CH3
+
C
N
NH
N N
S
NCH3
CH3
SuccinateDehydrogenase
MTT Formazan
![Page 6: Advantages and Limitations of Cell Culture Models in Pediatric Drug Development Peter C. Adamson, M.D. The Children’s Hospital of Philadelphia.](https://reader036.fdocuments.us/reader036/viewer/2022062519/5697bfca1a28abf838ca9606/html5/thumbnails/6.jpg)
Leukemia NSCLC Small Cell Colon CNS Melanoma Ovarian Renal
NCI 60 Cell Line Screen
![Page 7: Advantages and Limitations of Cell Culture Models in Pediatric Drug Development Peter C. Adamson, M.D. The Children’s Hospital of Philadelphia.](https://reader036.fdocuments.us/reader036/viewer/2022062519/5697bfca1a28abf838ca9606/html5/thumbnails/7.jpg)
Non-Clonogenic Assays MTT XTT SRB Trypan Blue DiscAssay FDA TACs Hoechst
WST-1 Acid Phosphatase DIMScan MTS Brd-U Luminescent-ATP
![Page 8: Advantages and Limitations of Cell Culture Models in Pediatric Drug Development Peter C. Adamson, M.D. The Children’s Hospital of Philadelphia.](https://reader036.fdocuments.us/reader036/viewer/2022062519/5697bfca1a28abf838ca9606/html5/thumbnails/8.jpg)
Non-Clonogenic Assays
Non-clonogenic assay ≈
Clonogenic assay ≈
Viable cell number ≈
In vivo cell growth ≈
Tumor growth in patient
![Page 9: Advantages and Limitations of Cell Culture Models in Pediatric Drug Development Peter C. Adamson, M.D. The Children’s Hospital of Philadelphia.](https://reader036.fdocuments.us/reader036/viewer/2022062519/5697bfca1a28abf838ca9606/html5/thumbnails/9.jpg)
Use of Cell Culture Models
Drug discovery Cellular pharmacology Study mechanism of action Study drug resistance As pediatric tumor models
Drug activity Dose (concentration)-schedule dependence Drug combinations
![Page 10: Advantages and Limitations of Cell Culture Models in Pediatric Drug Development Peter C. Adamson, M.D. The Children’s Hospital of Philadelphia.](https://reader036.fdocuments.us/reader036/viewer/2022062519/5697bfca1a28abf838ca9606/html5/thumbnails/10.jpg)
Limitations of Cell Culture Models Cell lines undergo transformation to allow for in
vitro growth Drugs may require metabolic activation or have
active metabolites Potential differences in drug exposure
Protein binding Drug disposition not modeled
Differences in tumor micro-environment Lack of vascularization Hypoxia
Other limitations…
![Page 11: Advantages and Limitations of Cell Culture Models in Pediatric Drug Development Peter C. Adamson, M.D. The Children’s Hospital of Philadelphia.](https://reader036.fdocuments.us/reader036/viewer/2022062519/5697bfca1a28abf838ca9606/html5/thumbnails/11.jpg)
Advantages of Cell Culture Models Not labor intensive Relatively low cost Moderate throughput capabilities Ability to study multiple cell lines Ability to study multiple combinations of drugs
Only system that mathematically determines synergy, additivity, and antagonism
![Page 12: Advantages and Limitations of Cell Culture Models in Pediatric Drug Development Peter C. Adamson, M.D. The Children’s Hospital of Philadelphia.](https://reader036.fdocuments.us/reader036/viewer/2022062519/5697bfca1a28abf838ca9606/html5/thumbnails/12.jpg)
Example: Determination of Synergy Problems with the “addition” method
Drug A 25% cell kill Drug B 25% cell kill Drug A + Drug B > 50% cell kill - synergy?
It’s not that simple Drug A 70% cell kill Drug B 70% cell kill Drug A + Drug B = 140% cell kill?
![Page 13: Advantages and Limitations of Cell Culture Models in Pediatric Drug Development Peter C. Adamson, M.D. The Children’s Hospital of Philadelphia.](https://reader036.fdocuments.us/reader036/viewer/2022062519/5697bfca1a28abf838ca9606/html5/thumbnails/13.jpg)
Median Effect Model
![Page 14: Advantages and Limitations of Cell Culture Models in Pediatric Drug Development Peter C. Adamson, M.D. The Children’s Hospital of Philadelphia.](https://reader036.fdocuments.us/reader036/viewer/2022062519/5697bfca1a28abf838ca9606/html5/thumbnails/14.jpg)
Example: Activity in Pediatric Tumors
BMS 247550 is an analog of epothilone B that binds tubulin, stabilizes mictrotubules by inhibiting tubulin depolymerization, blocks mitosis and causes apoptosis.
BMS 247550 is cytotoxic in taxane resistant tumors and tumor cell lines expressing the multidrug resistance phenotype (MDR).
Fox, Stover, Widemann, Fojo, Balis (AACR 2003)
![Page 15: Advantages and Limitations of Cell Culture Models in Pediatric Drug Development Peter C. Adamson, M.D. The Children’s Hospital of Philadelphia.](https://reader036.fdocuments.us/reader036/viewer/2022062519/5697bfca1a28abf838ca9606/html5/thumbnails/15.jpg)
BMS 247550: Pre-clinical Activity
IC50 (nM)
Cell Line BMS247550 Paclitaxel Vincristine Vinorelbine
HOS 8.6 ± 0.4 0.4 ± 0.03 44.7 ± 1.0 10.6 ± 0.4LD 8.2 ± 0.4 2.0 ± 0.2 5.0 ± 0.5 4.9 ± 3.1RD 16.8 ± 6.9 0.6 ± 0.03 38.4 ± 2.0 18.0 ± 0.6Daoy 9.2 ± 0.2 14.4 ± 0.5 14.9 ± 0.4 20.1 ± 1.1SK-N-AS 11.7 ± 1.3 8.6 ± 2.3 4.7 ± 0.4 0.8 ± 0.1G401 7.9 ± 0.1 6.8 ± 0.5 5.2 ± 0.1 1.9 ± 0.2
Daoy - - + + P S P S
SKNAS - - + + P S P S
LD - - + + P S P S
RD - - + + P S P S
HOS - - + + P S P S
G401 - - + + P S P S
46K
Fox, Stover, Widemann, Fojo, Balis (AACR 2003)
![Page 16: Advantages and Limitations of Cell Culture Models in Pediatric Drug Development Peter C. Adamson, M.D. The Children’s Hospital of Philadelphia.](https://reader036.fdocuments.us/reader036/viewer/2022062519/5697bfca1a28abf838ca9606/html5/thumbnails/16.jpg)
Example: Integration of New Agents
Induct
ion
Consolid
Mai
ntIM DDI
VCRVCRL-AspL-AspDNMDNMPDNPDN
IT MTXIT MTXIT Ara-CIT Ara-C
6-MP6-MPAra-CAra-CCTXCTXVCRVCR
Peg-ASPPeg-ASPC-XRTC-XRTIT MTXIT MTX
6-MP6-MPIV-MTXIV-MTX
Peg-ASPPeg-ASPIT MTXIT MTX
VCRVCRL-AspL-AspDoxDoxCTXCTX6-TG6-TGAra-CAra-CDexDex
IT MTXIT MTX
6-MP6-MPMTXMTX
VCR/PDNVCR/PDNIT MTXIT MTX
IMDI
6-MP6-MPIV-MTXIV-MTX
Peg-ASPPeg-ASPIT MTXIT MTX
VCRVCRL-AspL-AspDoxDoxCTXCTX6-TG6-TGAra-CAra-CDexDex
IT MTXIT MTX
High-Risk ALL Therapy
506U? ?
![Page 17: Advantages and Limitations of Cell Culture Models in Pediatric Drug Development Peter C. Adamson, M.D. The Children’s Hospital of Philadelphia.](https://reader036.fdocuments.us/reader036/viewer/2022062519/5697bfca1a28abf838ca9606/html5/thumbnails/17.jpg)
Asparaginase + 506U
0
20
40
60
80
100
0.001 0.01 0.1 1 10 100
MOLT4
Nelarabine (µM)
0
20
40
60
80
100
0.001 0.01 0.1 1 10 100
CEM
Nelarabine (µM)
Nelarabine --> Asn [-]
Asn [-] --> Nelarabine
% S
urv
ival
Jayaprakash, Adamson, Lampkin, Berg, Balis, Fox (AACR 2004)
![Page 18: Advantages and Limitations of Cell Culture Models in Pediatric Drug Development Peter C. Adamson, M.D. The Children’s Hospital of Philadelphia.](https://reader036.fdocuments.us/reader036/viewer/2022062519/5697bfca1a28abf838ca9606/html5/thumbnails/18.jpg)
Perspectives on Cell Culture Models
In vitro models are a cost efficient method to search for activity, but mechanistic based approaches likely will have higher yield
In vitro models can further our understanding of drug action in pediatric tumors
Moderate throughput is advantageous, especially when studying drug combinations
![Page 19: Advantages and Limitations of Cell Culture Models in Pediatric Drug Development Peter C. Adamson, M.D. The Children’s Hospital of Philadelphia.](https://reader036.fdocuments.us/reader036/viewer/2022062519/5697bfca1a28abf838ca9606/html5/thumbnails/19.jpg)
Perspectives on Cell Culture Models
For most cytotoxic agents, if it does not work in vitro, it will not work in vivo
If it takes supra-pharmacologic concentrations in vitro to have an effect, it will likely not fare well in vivo
If it works well in vitro, there is a reasonable likelihood that it will do absolutely nothing in vivo